Hutchmed/$HCM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Hutchmed
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Ticker
$HCM
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Hong Kong, Hong Kong
Employees
1,811
ISIN
US44842L1035
Website
Hutchmed Metrics
BasicAdvanced
$2.7B
407.51
$0.04
0.75
-
Price and volume
Market cap
$2.7B
Beta
0.75
52-week high
$18.00
52-week low
$11.51
Average daily volume
82K
Financial strength
Current ratio
2.832
Quick ratio
2.677
Long term debt to equity
8.23
Total debt to equity
11.637
Interest coverage (TTM)
-15.22%
Profitability
EBITDA (TTM)
-31.364
Gross margin (TTM)
10.98%
Net profit margin (TTM)
5.99%
Operating margin (TTM)
-6.94%
Effective tax rate (TTM)
15.85%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-2.14%
Return on equity (TTM)
5.04%
Valuation
Price to earnings (TTM)
407.51
Price to revenue (TTM)
22.123
Price to book
2.64
Price to tangible book (TTM)
2.65
Price to free cash flow (TTM)
-799.647
Free cash flow yield (TTM)
-0.13%
Free cash flow per share (TTM)
-2.04%
Growth
Revenue change (TTM)
-24.80%
Earnings per share change (TTM)
-66.28%
3-year revenue growth (CAGR)
20.96%
10-year revenue growth (CAGR)
21.85%
3-year earnings per share growth (CAGR)
-45.71%
10-year earnings per share growth (CAGR)
-4.35%
Bulls say / Bears say
HUTCHMED reported a net income of $100.8 million in fiscal 2023, a significant turnaround from the previous year's net loss of $360.8 million, driven by a 97% increase in revenue to $838 million. (markets.businessinsider.com)
The company's oncology product revenue grew by 59% in the first half of 2024, contributing to a total Oncology/Immunology consolidated revenue of $168.7 million, indicating strong commercial progress. (investor.wedbush.com)
Analysts have set a mean price target of $25.75 for HUTCHMED, suggesting a potential upside of 68.3% from the current trading price. (nasdaq.com)
HSBC downgraded HUTCHMED's stock from a 'buy' rating to a 'hold' rating on May 13, 2025, indicating potential concerns about the company's future performance. (defenseworld.net)
The average one-year price target for HUTCHMED has been revised down by 10.68% to $16.92, reflecting a more cautious outlook from analysts. (fintel.io)
Despite recent profitability, the company's stock price has experienced volatility, with a 52-week range between $11.51 and $21.50, which may concern risk-averse investors. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
Hutchmed News
AllArticlesVideos
HUTCHMED to Announce 2025 Half-Year Financial Results
GlobeNewsWire·1 week ago
HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy
GlobeNewsWire·2 weeks ago
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hutchmed stock?
Hutchmed (HCM) has a market cap of $2.7B as of July 11, 2025.
What is the P/E ratio for Hutchmed stock?
The price to earnings (P/E) ratio for Hutchmed (HCM) stock is 407.51 as of July 11, 2025.
Does Hutchmed stock pay dividends?
No, Hutchmed (HCM) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Hutchmed dividend payment date?
Hutchmed (HCM) stock does not pay dividends to its shareholders.
What is the beta indicator for Hutchmed?
Hutchmed (HCM) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.